High density of CXCL12-positive immune cell infiltration predicts chemosensitivity and recurrence-free survival in ovarian carcinoma.

"Declarations Conflict of interestThe authors declare that they have no competing interests. Ethics approvalThis study was approved by the regional ethics committee of the University Hospital Basel Switzerland. Finally, the study was performed according to the guidelines of the institutional review boards (IRB) of the participating institutions as previously published [47–50]. The need for patient consent for studies using this TMA was originally waived by the ethics committee of northwestern Switzerland (EKNZ). Currently the TMA is handed to the biobank of pathology of the University Hospital Basel. Consent to participateThe patients/participants provided their written informed consent to participate in this study. The consent was waived by the ethics committee (Ethikkommission Nordwest- und Zentralschweiz). Conflict of interest The authors declare that they have no competing interests."

"Funding Open access funding provided by University of Basel."